{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:08:01Z","timestamp":1780592881797,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjsurg.2026.116901","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:53:13Z","timestamp":1772524393000},"page":"116901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Axillary lymph node dissection is not routinely indicated in patients with sentinel lymph node residual micrometastases following neoadjuvant systemic therapy"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3896-2542","authenticated-orcid":false,"given":"Kinan","family":"Mokbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefah","family":"Mokbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2026.116901_bib1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.amjsurg.2026.116901_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomized, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib3","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study","volume":"43","author":"Montagna","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","article-title":"Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy","volume":"10","author":"Montagna","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.amjsurg.2026.116901_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","article-title":"De-escalation of nodal surgery in clinically node-positive breast cancer","volume":"160","author":"Cabioglu","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.amjsurg.2026.116901_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104411","article-title":"Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol","volume":"80","author":"van Hemert","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.amjsurg.2026.116901_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10549-008-0021-6","article-title":"The clinical significance of sentinel lymph node micrometastasis in breast cancer","volume":"114","author":"Patani","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjsurg.2026.116901_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-024-01874-x","article-title":"Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy","volume":"26","author":"Lee","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.amjsurg.2026.116901_bib12","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1038\/s41598-021-88442-x","article-title":"Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy","volume":"11","author":"Chun","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjsurg.2026.116901_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35567","article-title":"Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy","volume":"131","author":"Shin","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2026.116901_bib14","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjsurg.2026.116901_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjsurg.2026.116901_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10238-025-01869-8","article-title":"Axillary lymph node dissection offers no survival benefit in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy","volume":"25","author":"Zhang","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.amjsurg.2026.116901_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","article-title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): an international, retrospective cohort study","volume":"27","author":"Montagna","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib18","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","article-title":"Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from >1500 patients on the I-SPY2 clinical trial","volume":"32","author":"Boughey","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib19","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy in breast cancer","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjsurg.2026.116901_bib20","first-page":"195","article-title":"Regional nodal irradiation (RNI) in breast cancer patients with residual isolated tumor cells or micrometastatic nodal disease after neoadjuvant chemotherapy","volume":"38","author":"Kim","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib21","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.3390\/cancers14143341","article-title":"Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells","volume":"14","author":"Crook","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjsurg.2026.116901_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clbc.2023.10.003","article-title":"Unlocking the power of the homing phenomenon in breast cancer management: implications for personalized therapy and improved outcomes","volume":"24","author":"Mokbel","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.amjsurg.2026.116901_bib23","first-page":"754","article-title":"Liquid biopsy in breast cancer: a practical guide for surgeons Gland","volume":"14","author":"Venkataraman","year":"2025","journal-title":"Surg"},{"key":"10.1016\/j.amjsurg.2026.116901_bib24","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3390\/cancers16122172","article-title":"Wire-free targeted axillary dissection: a pooled analysis of outcomes following neoadjuvant chemotherapy","volume":"16","author":"Varghese","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.amjsurg.2026.116901_bib25","article-title":"Trastuzumab deruxtecan in residual HER2-Positive early breast cancer","author":"Loibl","year":"2025","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.amjsurg.2026.116901_bib26","first-page":"S0923","article-title":"Overall survival with abemaciclib in early breast cancer","author":"Johnston","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.amjsurg.2026.116901_bib27","doi-asserted-by":"crossref","first-page":"7472","DOI":"10.21037\/tcr-2025-1837","article-title":"Translating NSABP B-51 findings into practice: rethinking regional nodal irradiation in breast cancer","volume":"14","author":"Mokbel","year":"2025","journal-title":"Transl Cancer Res"},{"issue":"3","key":"10.1016\/j.amjsurg.2026.116901_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/annonc\/mdu561","article-title":"Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey","volume":"26","author":"Belkacemi","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.amjsurg.2026.116901_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110445","article-title":"AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025","volume":"51","author":"Reimer","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.amjsurg.2026.116901_bib31","series-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 3.2024)","author":"Network","year":"2024"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.116901_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.amjsurg.2026.116901_bib33","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.amjsurg.2026.116901_bib34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"KEYNOTE-522 investigators. Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjsurg.2026.116901_bib35","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.23.01214","article-title":"Patient-Reported outcomes in OlympiA: a phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1\/2Mutations and high-risk human epidermal growth factor receptor 2-Negative early breast cancer","volume":"42","author":"Ganz","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296102600084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296102600084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:54:34Z","timestamp":1780592074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296102600084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S000296102600084X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.116901","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary lymph node dissection is not routinely indicated in patients with sentinel lymph node residual micrometastases following neoadjuvant systemic therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.116901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116901"}}